The Russian Federal Antimonopoly Service has approved a ceiling price for a Russian medication used to treat Fabry disease. The maximum price set is 110,980 rubles per bottle of the 35 mg dosage solution. This is a significant reduction from the registered price of the reference drug, which stands at 184,966 rubles.
“Agreeing on the price of this drug will increase its availability for citizens. In medical organizations it will be provided free of charge as part of the program of state guarantees of free medical care,” the FAS said. As per the department’s instructions, the agreed maximum selling prices for Fabrazim, a foreign reference medicinal product, are an impressive 40% lower than the registered prices.
In August, Russian biotech company Petrovax said it had received marketing authorization for its orphan drug Fabagale, which is used for long-term enzyme replacement therapy for the disease.
